NASDAQ:LXRX Lexicon Pharmaceuticals (LXRX) Stock Price, News & Analysis $2.55 +0.26 (+11.35%) Closing price 04:00 PM EasternExtended Trading$2.53 -0.02 (-0.78%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lexicon Pharmaceuticals Stock (NASDAQ:LXRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LXRX alerts:Sign Up Key Stats Today's Range$2.28▼$2.5550-Day Range$1.55▼$2.5552-Week Range$0.80▼$2.55Volume39.45 million shsAverage Volume2.22 million shsMarket Capitalization$1.13 billionP/E RatioN/ADividend YieldN/APrice Target$4.55Consensus RatingHold Company Overview Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases. The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy. In addition to this marketed asset, Lexicon maintains a diversified pipeline with programs spanning metabolic diseases, neuropathic pain, and rare genetic disorders. Key development candidates include small-molecule inhibitors modulating glucose transport and neuroreceptor activity, each designed to address unmet medical needs through precise mechanism-based intervention. Founded in 1995 and headquartered in The Woodlands, Texas, Lexicon Pharmaceuticals has been publicly traded on the NASDAQ exchange since 2000. The company collaborates with academic institutions, strategic partners and patient advocacy groups to advance its research and expand clinical development globally. With a core scientific team experienced in genomics, medicinal chemistry and clinical development, Lexicon continues to pursue innovative solutions aimed at improving patient outcomes across a variety of therapeutic areas.AI Generated. May Contain Errors. Read More Lexicon Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreLXRX MarketRank™: Lexicon Pharmaceuticals scored higher than 47% of companies evaluated by MarketBeat, and ranked 577th out of 850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingLexicon Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialLexicon Pharmaceuticals has a consensus price target of $4.55, representing about 78.4% upside from its current price of $2.55.Amount of Analyst CoverageLexicon Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Lexicon Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Lexicon Pharmaceuticals are expected to decrease in the coming year, from ($0.17) to ($0.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexicon Pharmaceuticals is -36.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexicon Pharmaceuticals is -36.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexicon Pharmaceuticals has a P/B Ratio of 8.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lexicon Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.66% of the float of Lexicon Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLexicon Pharmaceuticals has a short interest ratio ("days to cover") of 12.62, which indicates bearish sentiment.Change versus previous monthShort interest in Lexicon Pharmaceuticals has recently decreased by 2.98%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLexicon Pharmaceuticals does not currently pay a dividend.Dividend GrowthLexicon Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.0 / 5News Sentiment1.44 News SentimentLexicon Pharmaceuticals has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Lexicon Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest13 people have searched for LXRX on MarketBeat in the last 30 days. This is an increase of 117% compared to the previous 30 days.MarketBeat Follows4 people have added Lexicon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lexicon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders14.00% of the stock of Lexicon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.70% of the stock of Lexicon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lexicon Pharmaceuticals' insider trading history. Receive LXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LXRX Stock News HeadlinesLexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Passes Above 200-Day Moving Average - Should You Sell?June 26 at 2:40 AM | americanbankingnews.comIs Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now?June 11, 2026 | finance.yahoo.comA drilling crew just broke a record nobody expectedA drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of Energy projected would take 64. They reached DOE's 2035 performance targets twelve years early, cutting costs in half within 18 months. When Congress moved to cut solar and wind tax credits, this energy source kept its full credits through 2033. One company has been building in this space for sixty years, and a July 4th catalyst is now 12 days away.June 26 at 1:00 AM | Behind the Markets (Ad)How The Lexicon Pharmaceuticals (LXRX) Investment Narrative Is Evolving With Quiet Analyst UpdatesJune 4, 2026 | finance.yahoo.comLexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific SessionsJune 3, 2026 | globenewswire.comLexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comSA analyst upgrades/downgrades: SMCI, AMZN, SFM, LXRXMay 27, 2026 | msn.comLexicon Pharmaceuticals: Uncertainty Clouds The Bull Case (Rating Downgrade)May 26, 2026 | seekingalpha.comSee More Headlines LXRX Stock Analysis - Frequently Asked Questions How have LXRX shares performed this year? Lexicon Pharmaceuticals' stock was trading at $1.15 at the beginning of 2026. Since then, LXRX stock has increased by 121.7% and is now trading at $2.55. How were Lexicon Pharmaceuticals' earnings last quarter? Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported $0.00 EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.04. The biopharmaceutical company earned $21.10 million during the quarter, compared to analysts' expectations of $9.79 million. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 18.64% and a negative net margin of 37.46%. Read the conference call transcript. Who are Lexicon Pharmaceuticals' major shareholders? Top institutional shareholders of Lexicon Pharmaceuticals include Siren L.L.C. (9.97%), Renaissance Technologies LLC (0.36%), ADAR1 Capital Management LLC (0.17%) and Bank of America Corp DE (0.12%). Insiders that own company stock include Raymond Debbane, Invus Global Management, Llc, Lonnel Coats, Jeffrey L Wade and Wendy Mcdermott. View institutional ownership trends. How do I buy shares of Lexicon Pharmaceuticals? Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lexicon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lexicon Pharmaceuticals investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Moderna (MRNA). Company Calendar Last Earnings5/07/2026Today6/26/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (14m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 LXRX's financial health is in the Green zone, according to TradeSmith. LXRX has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:LXRX Previous SymbolNASDAQ:LEXG CIK1062822 Webwww.lexpharma.com Phone(281) 863-3000Fax281-863-8010Employees140Year Founded1995Price Target and Rating Average Price Target for Lexicon Pharmaceuticals$4.55 High Price Target$6.00 Low Price Target$3.10 Potential Upside/Downside+78.4%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$50.34 million Net Margins-37.46% Pretax Margin-37.46% Return on Equity-18.64% Return on Assets-11.79% Debt Debt-to-Equity Ratio0.24 Current Ratio18.80 Quick Ratio18.77 Sales & Book Value Annual Sales$49.80 million Price / Sales22.75 Cash FlowN/A Price / Cash FlowN/A Book Value$0.30 per share Price / Book8.50Miscellaneous Outstanding Shares444,200,000Free Float382,009,000Market Cap$1.13 billion OptionableOptionable Beta1.07 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:LXRX) was last updated on 6/26/2026 by MarketBeat.com Staff. From Our PartnersProblems at SpaceX: time to get out?Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredElon’s message for AmericaElon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...Stansberry Research | SponsoredSolar is dead. Here’s what replaces it.Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-car...Behind the Markets | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
